Sean Moloughney01.27.09
Chr. Hansen has acquired Urex Biotech Inc. in an effort to expand its development of probiotics for dietary supplements, while also entering a North American distribution agreement with Cyvex Nutrition.
“I am very pleased with this agreement,” Henrik Dalboege, executive vice president, Health & Nutrition Division, Chr. Hansen, said of the Urex acquisition. “As a division our strategy is to continue the recent year’s positive development through organic growth or through relevant acquisitions—and Urex is a perfect strategic fit for us.”
The Health & Nutrition Division experienced more than 20% organic growth in 2007-2008 and will focus on developing new products for the dietary supplement industry and the pharmaceutical industry, with primary emphasis on probiotics.
Chr. Hansen and Urex Biotech Inc entered a strategic alliance in 2004 to develop and promote therapeutic solutions for women’s health issues based on proven probiotic strains.
Urex is an oral probiotic concept that restores and maintains a healthy vaginal flora, which may reduce the risk of infections. Over the last few years nine clinical studies conducted in several countries have been published using the oral formulation and numerous others are currently underway.
“For probiotics, documentation is key and Urex–cap-5 is among the best documented probiotic concepts in the world,” said Mr. Dalboege. “Furthermore, the concept fits perfectly to our existing product portfolio within the category women’s health and to our other probiotic solutions for gastrointestinal health and immune health.”
Chr. Hansen North America has also entered an agreement with Cyvex Nutrition, which will become the exclusive distributor in the dietary supplement channel for its line of phytonutrients.
“Chr. Hansen is a perfect partner for developing unique phytonutrients for the dietary supplement industry,” said Gilbert Gluck, CEO, Cyvex. “Chr. Hansen expertise in plant extracts uniquely positions Cyvex in marketing new and exciting nutraceuticals.”
“I am very pleased with this agreement,” Henrik Dalboege, executive vice president, Health & Nutrition Division, Chr. Hansen, said of the Urex acquisition. “As a division our strategy is to continue the recent year’s positive development through organic growth or through relevant acquisitions—and Urex is a perfect strategic fit for us.”
The Health & Nutrition Division experienced more than 20% organic growth in 2007-2008 and will focus on developing new products for the dietary supplement industry and the pharmaceutical industry, with primary emphasis on probiotics.
Chr. Hansen and Urex Biotech Inc entered a strategic alliance in 2004 to develop and promote therapeutic solutions for women’s health issues based on proven probiotic strains.
Urex is an oral probiotic concept that restores and maintains a healthy vaginal flora, which may reduce the risk of infections. Over the last few years nine clinical studies conducted in several countries have been published using the oral formulation and numerous others are currently underway.
“For probiotics, documentation is key and Urex–cap-5 is among the best documented probiotic concepts in the world,” said Mr. Dalboege. “Furthermore, the concept fits perfectly to our existing product portfolio within the category women’s health and to our other probiotic solutions for gastrointestinal health and immune health.”
Chr. Hansen North America has also entered an agreement with Cyvex Nutrition, which will become the exclusive distributor in the dietary supplement channel for its line of phytonutrients.
“Chr. Hansen is a perfect partner for developing unique phytonutrients for the dietary supplement industry,” said Gilbert Gluck, CEO, Cyvex. “Chr. Hansen expertise in plant extracts uniquely positions Cyvex in marketing new and exciting nutraceuticals.”
